Cognitive Changes following Bilateral Deep Brain Stimulation of Subthalamic Nucleus in Parkinson’s Disease: A Meta-Analysis

Table 1

Basic information of included studies (STN-DBS versus control).

Study	Number of patients	Age	Duration of disease	Duration of follow-up	LED
Rothlind, 2015 [12]	84/116	61.3 ± 8.5/62.3 ± 8.9	11.0 ± 5.0/12.8 ± 5.5	6 m	1291.5 ± 549.8/1290.1 ± 550.2
Witt, 2013 [13]	31/31	59.8 ± 7.5/58.9 ± 9.6	13.3 ± 5.5/13.1 ± 5.3	6 m	1244 ± 527/1204 ± 522
Daniels, 2010 [14]	60/63	60.2 ± 7.9/59.4 ± 7.5	13.8 ± 6.3/14.0 ± 6.1	6 m	1203 ± 535/1142 ± 463
Cilia, 2007 [15]	20/12	59.1 ± 7.4/61.2 ± 5.3	13.2 ± 3.1/15.2 ± 4.4	1 y	951 ± 465
Zangaglia, 2009 [16]	32/33	58.84 ± 7.70/62.52 ± 6.82	11.84 ± 5.07/9.97 ± 4.86	6, 12, 24 m	932.94 ± 409.86/1043.51 ± 304.87
York, 2008 [17]	23/27	59.5 ± 11.8/66.7 ± 8.7	12.0 ± 5.5/4.7 ± 4.4	7.1 m	1009.8 ± 445.3/358.9 ± 287.0
Williams, 2011 [18]	19/18	62.1 ± 10.3/66.6 ± 9.0	10.1 ± 6.24/10.1 ± 6.24	2 y	1017.6 ± 411.2/486.4 ± 293.0
Merola, 2014 [19]	19/16	60.11 ± 5.62/60.87 ± 5.81	12.94 ± 2.15/11.06 ± 2.93	6 y	1120 ± 328.79/1252.73 ± 430.02
Castelli, 2010 [20]	27/31	60.6 ± 6.7/60.2 ± 6.6	15.3 ± 5.1/15.6 ± 5.2	1 y	1046.1 ± 436.4/1046.1 ± 436.4
Smeding, 2006 [21]	99/36	57.9 ± 8.1/63.0 ± 9.1	13.7 ± 6.1/10.4 ± 4.6	6 m	899.3 ± 498.0/629.6 ± 304.9

Family name of the first author and year of publication.
Years, mean ± standard deviation.
Month, mean ± standard deviation.
Levodopa equivalent dose, mg/day, mean ± standard deviation.